Clinical trial NCT04548700: Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL
Official title: Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Liposomal Mitoxantrone Hydrochloride Injection Combined With Cyclophosphamide, Vincristine and Prednisone in the Treatment of Untreated PTCL
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Treatment-naïve
Peripheral T Cell Lymphoma
Lead sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2020-09-14
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multicentre, open-label, single-arm, phase Ib clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and Prednisone in the frontline treatment of patients with peripheral T cell lymphoma (PTCL).

Detailed description: The study is to investigate the safety, tolerability, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and Prednisone in the frontline treatment of patients with PTCL by conducting in two stages, Dose-finding stage and Dose-expansion stage.In Dose-finding stage, patients with treatment-naïve PTCL will be assigned to receive sequentially higher doses of liposomal mitoxantrone hydrochloride ranging from 12 to 18 mg/m2 plus Cyclophosphamide, Vincristine and Prednisone (28 days per cycle). The dose escalation will follow the classic 3+3 design. The recommended Phase 2 dose (RP2D) of liposomal mitoxantrone hydrochloride will be determined according to the Dose-finding results. In Dose-expansion stage, additional patients will be recruited into two groups, the Q4W group（28 days per cycle）and the Q3W group（21 days per cycle）, to receive liposomal mitoxantrone hydrochloride at the RP2D combined with Cyclophosphamide, Vincristine and Prednisone. All patients will receive the treatment for the planned 6 cycles or until disease progression or unacceptable drug-related adverse events.

Eligibility criteria: Inclusion Criteria:

1. Subjects fully understand and voluntarily participate in this study and sign informed consent
2. Age ≥18, ≤70years, no gender limitation
3. Histologically confirmed diagnosis of treatment-naïve PTCL. Eligible histologies are limited to the following: Peripheral T-cell lymphoma - not otherwise specified (PTCL-NOS),Angioimmunoblastic T-cell lymphoma (AITL), ALK -positive Anaplastic Large cell Lymphoma（ALCL）, ALK-negative ALCL; Other PTCL that investigators consider to be appropriate to be enrolled
4. PTCL with fluorodeoxyglucose (FDG) avidity that can be evaluated by PET/CT
5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1
6. The following required baseline laboratory data: Absolute neutrophil count (ANC) ≥1.5×109/L, Platelet count (PLT) ≥75×109/L, Hemoglobin(HB)≥ 80g/L, Total bilirubin (TBIL) ≤1.5X upper limit of normal (ULN) , Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5X ULN , Serum creatinine (Scr) ≤1.5X ULN
7. Females of childbearing potential must have a negative serum beta human chorionic gonadotrophin (β-hCG) pregnancy test result prior to enrollment and must agree to use an effective contraception method for the duration of the study treatment and 12 months after the last dose of study therapy
8. Males of reproductive potential must agree to use an effective contraceptive method for the duration of the study treatment and 12 months after the last dose of study therapy

Exclusion Criteria:

1. Current diagnosis of any of the following: extranodal natural killer/T-cell lymphoma, nasal type(NKTCL), Mycosis fungoides (MF)/ Sézary syndrome (SS), Primary cutaneous ALCL，and Adult T-cell leukemia/lymphoma
2. Leukemic phase of lymphoma (≥20% lymphoma cell in the bone marrow), or central nervous system (CNS) involvement, or hemophagocytic syndrome
3. Life expectancy \< 6 months
4. History of allergy to anthracyclines or liposomes
5. History of contraindications to cyclophosphamide, vincristine or prednisone
6. Prior anti-lymphoma therapy except short-term or low-dose corticosteroid treatment
7. Impaired cardiac function or significant cardiac disease
8. Positive test results for HBsAg antigen and HBV-DNA, or hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) antibody
9. Major surgery within 4～6weeks prior to screening. Or have a surgical schedule during the study
10. A serious infection within 4 weeks prior to screening and not suitable for the study according to the judgment of the investigator
11. Uncontrolled hypertension at screening
12. Uncontrolled diabetes at screening
13. History of active visceral hemorrhage in the recent 3 months prior to screening
14. History of other tumors in the past five years prior to screening. Patients with curable tumors (such as skin basal cell carcinoma, carcinoma in situ of the cervix or of the breast, intramucosal carcinoma in situ of the gastrointestinal tract or localized prostate cancer) could be enrolled after completely cured
15. History of solid organ transplantation
16. Known psychiatric disorders or cognitive disorder
17. Known alcohol or drug abuse
18. Pregnant or breastfeeding women
19. Not suitable for this study as determined by the investigator due to other reasons

Primary outcomes:
measure: Dose-finding stage: The incidence of dose limited toxicities (DLTs)
timeFrame: Cycle 1 (28 days)
measure: Dose-finding stage:The incidence of AE and SAE
timeFrame: up to 24 weeks
measure: Dose-expansion stage: The incidence of AE and SAE
timeFrame: up to 18-24 weeks
Secondary outcomes:
measure: Dose-finding stage: complete response(CR) rate
timeFrame: up to 24 weeks
measure: Dose-finding stage: duration of complete response（DoCR）
timeFrame: Throughout study completion,an average of 18 months
measure: Dose-finding stage: overall response rate (ORR)
timeFrame: up to 24 weeks
measure: Dose-finding stage: progression-free survival（PFS）
timeFrame: Throughout study completion,an average of 18 months
measure: Dose-finding stage：the pharmacokinetic parameters Cmax
timeFrame: Cycle 1 to Cycle 6(each cycle is 28 days)
measure: Dose-finding stage：the pharmacokinetic parameters AUC0-t
timeFrame: Cycle 1 to Cycle 6(each cycle is 28 days)
measure: Dose-expansion stage: CR rate
timeFrame: up to 24 weeks
measure: Dose-expansion stage: DoCR
timeFrame: Throughout study completion,an average of 18 months
measure: Dose-expansion stage: ORR
timeFrame: up to 18-24 weeks
measure: Dose-expansion stage: PFS
timeFrame: Throughout study completion,an average of 18 months
measure: Dose-expansion stage: the pharmacokinetic parameters Cmax
timeFrame: Cycle 1(each cycle is 21or28 days)
measure: Dose-expansion stage: the pharmacokinetic parameters AUC0-t
timeFrame: Cycle 1(each cycle is 21or28 days)
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
state: Guangdong
Study officials:
affiliation: Sun Yat-sen University
name: Huiqiang Huang, Doctor
role: PRINCIPAL_INVESTIGATOR
References: